Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety of Fentanyl TAIFUN Treatment After Titrated Dose Administration and the Current Breakthrough Pain Treatment for Breakthrough Pain in Cancer Patients

NCT00822614 is registered in ClinicalTrials.gov with Akela Pharma, Inc. as lead sponsor.

NCT NCT00822614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00822614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety of Fentanyl TAIFUN Treatment After Titrated Dose Administration and the Current Breakthrough Pain Treatment for Breakthrough Pain in Cancer Patients
Lead sponsor
Akela Pharma, Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
December 31, 2008
Completion date
January 31, 2010
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breakthrough cancer pain